B Cell News and Research

RSS

Triple therapy reduces tumor burden and improves survival in glioblastoma models

A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled "Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT."

4 Apr 2025

CRISPR tool unveils genetic drivers of blood cell maturation

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.

4 Apr 2025

Cornell researchers discover brain mechanisms behind psilocybin's effects

Psilocybin is the active ingredient that gives so-called "magic mushrooms" their hallucinogenic kick. It also has a therapeutic potential for treating depression.

4 Apr 2025

Pancreatic cells show epigenetic marks before cancerous transformation

Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between normal and pancreatic cancer cells in mice, and that the normal cells may keep at least a temporary "memory" of those cancer-linked marks.

4 Apr 2025

Small molecular shifts can drastically alter encephalitis virus behavior

New research shows how small shifts in the molecular makeup of a virus can profoundly alter its fate. These shifts could turn a deadly pathogen into a harmless bug or supercharge a relatively benign virus, influencing its ability to infect humans and cause dangerous outbreaks.

4 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Study: Jumbo phages utilize EPI vesicles to evade bacterial immune response

In a growing global trend, bacteria have evolved new ways to maneuver around medical treatments for a variety of infections. The rising antibiotic resistance crisis poses a significant public health threat in hospitals and other settings, with infections resulting in millions of deaths in recent years.

4 Apr 2025

Key cellular mechanism affecting the function of mRNA vaccines revealed

A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science (IBS), has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics.

3 Apr 2025

New bacterial evolutionary map could lead to precision treatments for infections

The first-of-its-kind in-depth bacterial evolutionary map could pave the way for the development of precision treatments for certain antibiotic-resistant infections, such as urinary tract infections.

3 Apr 2025

New method traces development of nervous system and inner ear cells

Researchers at Karolinska Institutet have developed a method that shows how the nervous system and sensory organs are formed in an embryo.

3 Apr 2025

Drug-carrying DNA aptamers offer dual action against leukemia stem cells

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

3 Apr 2025

Smoothies with seeds may improve glycemic control, study shows

Blending whole fruits into smoothies may reduce glycemic spikes compared to eating fruit whole or drinking juice, especially when seeds are included. Researchers urge a re-evaluation of public health guidelines that currently limit smoothie intake.

3 Apr 2025

Sweetener saccharin revives old antibiotics by breaking bacterial defences

Saccharin destabilizes bacterial membranes and interferes with DNA replication, causing lysis and impairing virulence traits. The sweetener also re-sensitizes multidrug-resistant pathogens to antibiotics and disrupts stubborn biofilms.

3 Apr 2025

New thromboinflammation-on-a-chip model may revolutionize treatment of harmful blood clots

Blood clots are associated with life-threatening conditions such as sepsis, sickle cell disease, heart attack, and stroke.

3 Apr 2025

Study sheds light on how major cancer gene influences the success of PARP inhibitors

A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

3 Apr 2025

Study reveals how female hormones trigger opioid production for pain suppression

Scientists have discovered a new mechanism that acts via an immune cell and points toward a different way of treating chronic pain.

3 Apr 2025

Bach2 protein identified as key regulator in atopic dermatitis

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to social stress.

3 Apr 2025

Breakthrough research identifies small peptide for psoriasis treatment

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied topically in an emollient cream.

3 Apr 2025

NUZ-001 shows positive results in human 3D brain model

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results from an independent study undertaken in collaboration with Tessara Therapeutics (“Tessara”) will be presented by the group’s Principal Scientist and Alzheimer’s Disease expert, Dr Mark Greenough at the AD/PD 2025 Advances in Sciences & Therapy conference on April 2nd to 3rd.

3 Apr 2025

4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA

4basebio PLC (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

From 4basebio PLC 3 Apr 2025